Terns Pharmaceuticals (TERN) Income from Continuing Operations (2020 - 2023)
Historic Income from Continuing Operations for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.1 million.
- Terns Pharmaceuticals' Income from Continuing Operations fell 3127.45% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 4900.8%. This contributed to the annual value of -$89.6 million for FY2024, which is 78.76% up from last year.
- Terns Pharmaceuticals' Income from Continuing Operations amounted to -$21.1 million in Q4 2023, which was down 3127.45% from -$29.8 million recorded in Q3 2023.
- In the past 5 years, Terns Pharmaceuticals' Income from Continuing Operations ranged from a high of -$9.2 million in Q1 2020 and a low of -$29.8 million during Q3 2023
- Its 4-year average for Income from Continuing Operations is -$15.2 million, with a median of -$13.9 million in 2022.
- As far as peak fluctuations go, Terns Pharmaceuticals' Income from Continuing Operations tumbled by 210.51% in 2021, and later crashed by 7697.38% in 2023.
- Over the past 4 years, Terns Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$11.1 million in 2020, then fell by 29.0% to -$14.3 million in 2021, then decreased by 12.07% to -$16.1 million in 2022, then crashed by 31.27% to -$21.1 million in 2023.
- Its last three reported values are -$21.1 million in Q4 2023, -$29.8 million for Q3 2023, and -$17.9 million during Q2 2023.